These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37016946)

  • 21. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.
    van der Werf C; Nederend I; Hofman N; van Geloven N; Ebink C; Frohn-Mulder IM; Alings AM; Bosker HA; Bracke FA; van den Heuvel F; Waalewijn RA; Bikker H; van Tintelen JP; Bhuiyan ZA; van den Berg MP; Wilde AA
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):748-56. PubMed ID: 22787013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
    Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bradycardia Is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by RYR2 Mutations.
    Miyata K; Ohno S; Itoh H; Horie M
    Intern Med; 2018 Jul; 57(13):1813-1817. PubMed ID: 29434162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac ryanodine receptor calcium release deficiency syndrome.
    Sun B; Yao J; Ni M; Wei J; Zhong X; Guo W; Zhang L; Wang R; Belke D; Chen YX; Lieve KVV; Broendberg AK; Roston TM; Blankoff I; Kammeraad JA; von Alvensleben JC; Lazarte J; Vallmitjana A; Bohne LJ; Rose RA; Benitez R; Hove-Madsen L; Napolitano C; Hegele RA; Fill M; Sanatani S; Wilde AAM; Roberts JD; Priori SG; Jensen HK; Chen SRW
    Sci Transl Med; 2021 Feb; 13(579):. PubMed ID: 33536282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
    Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
    Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
    Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
    Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
    Leren IS; Saberniak J; Majid E; Haland TF; Edvardsen T; Haugaa KH
    Heart Rhythm; 2016 Feb; 13(2):433-40. PubMed ID: 26432584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
    Roston TM; Cunningham TC; Sanatani S
    Cardiol Young; 2017 Jan; 27(S1):S49-S56. PubMed ID: 28084961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
    Nof E; Belhassen B; Arad M; Bhuiyan ZA; Antzelevitch C; Rosso R; Fogelman R; Luria D; El-Ani D; Mannens MM; Viskin S; Eldar M; Wilde AA; Glikson M
    Heart Rhythm; 2011 Oct; 8(10):1546-52. PubMed ID: 21699856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Associated With Ryanodine Receptor (RyR2) Gene Mutations　- Long-Term Prognosis After Initiation of Medical Treatment.
    Kawata H; Ohno S; Aiba T; Sakaguchi H; Miyazaki A; Sumitomo N; Kamakura T; Nakajima I; Inoue YY; Miyamoto K; Okamura H; Noda T; Kusano K; Kamakura S; Miyamoto Y; Shiraishi I; Horie M; Shimizu W
    Circ J; 2016 Aug; 80(9):1907-15. PubMed ID: 27452199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome.
    Schneider HE; Steinmetz M; Krause U; Kriebel T; Ruschewski W; Paul T
    Clin Res Cardiol; 2013 Jan; 102(1):33-42. PubMed ID: 22821214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
    Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
    JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catecholaminergic Polymorphic Ventricular Tachycardia.
    Kim CW; Aronow WS; Dutta T; Frenkel D; Frishman WH
    Cardiol Rev; 2020; 28(6):325-331. PubMed ID: 31934898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
    Wangüemert F; Bosch Calero C; Pérez C; Campuzano O; Beltran-Alvarez P; Scornik FS; Iglesias A; Berne P; Allegue C; Ruiz Hernandez PM; Brugada J; Pérez GJ; Brugada R
    Heart Rhythm; 2015 Jul; 12(7):1636-43. PubMed ID: 25814417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Gao J; Makiyama T; Yamamoto Y; Kobayashi T; Aoki H; Maurissen TL; Wuriyanghai Y; Kashiwa A; Imamura T; Aizawa T; Huang H; Kohjitani H; Nishikawa M; Chonabayashi K; Fukuyama M; Manabe H; Nakau K; Wada T; Kato K; Toyoda F; Yoshida Y; Makita N; Woltjen K; Ohno S; Kurebayashi N; Murayama T; Sakurai T; Horie M; Kimura T
    Circ Arrhythm Electrophysiol; 2023 Mar; 16(3):e011387. PubMed ID: 36866681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Catecholaminergic polymorphic ventricular tachycardia.
    Liu N; Ruan Y; Priori SG
    Prog Cardiovasc Dis; 2008; 51(1):23-30. PubMed ID: 18634915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: A Translational Perspective for the Clinician-Scientist.
    Kallas D; Lamba A; Roston TM; Arslanova A; Franciosi S; Tibbits GF; Sanatani S
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
    Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
    Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
    Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.